Protect clinical trial data, intellectual property, and manufacturing systems. FrameworkMapper maps your security stack against CIS Controls and NIST CSF v2 — aligned with FDA cybersecurity guidance for drug manufacturers and clinical operations.
Why This Matters
Drug formulas, clinical trial data, and manufacturing systems are among the highest-value targets for sophisticated threat actors.
Pharmaceutical IP theft is among the most costly cybercrimes — drug formulas and clinical trial data are high-value targets for nation-state actors
Intelligence community assessment
FDA has issued cybersecurity guidance for drug manufacturing (21 CFR Part 11) and medical device security
FDA regulatory guidance
Pharma companies operating clinical sites are HIPAA covered entities or business associates — requiring HIPAA Security Rule compliance
HHS regulatory requirement
Supply chain attacks on pharmaceutical manufacturers can disrupt drug production and patient care
Industry risk analysis
Recommended Frameworks
FrameworkMapper supports all frameworks below, with pharma-tuned prioritization built in.
| Framework | Why It Applies | Status |
|---|---|---|
| CIS Controls v8.1 | Practical safeguards for both IT and OT/manufacturing environments | Strongly Recommended |
| NIST CSF v2 | Core risk management framework aligned with FDA cybersecurity expectations | Strongly Recommended |
| HIPAA Security Rule | Required for pharma organizations operating clinical sites or handling patient health information | Mandatory (if clinical operations) |
| NIST SP 800-53 | Applicable for pharma organizations working with government health agencies (NIH, DoD) | Conditional |
How FrameworkMapper Helps
Visualize how your security tools address CIS Controls across research, manufacturing, and clinical environments — a critical first step for FDA-aligned security programs.
Launch AggregatorToolMapper surfaces tools relevant for pharma environments including OT/ICS security solutions, clinical data protection, and IP security.
Launch ToolMapperCIS and NIST CSF assessments produce reports that support FDA 21 CFR Part 11 compliance documentation and clinical audit requirements.
View AssessmentsThe Universal Control Prioritization Algorithm uses seven factors, each weighted to reflect the regulatory intensity, IP protection requirements, and threat environment of pharmaceutical organizations.
Pharmaceuticals uses the SLTT (V06) weight profile as a proxy — heavily regulated environments with significant IP and clinical data obligations. A dedicated Pharmaceuticals profile is on the FrameworkMapper roadmap.
| Factor | Pharma Weight | What This Means |
|---|---|---|
| T Threat Relevance | 0.20 | Controls targeting nation-state IP theft, ransomware on manufacturing systems, and clinical data threats score higher |
| D Dependency Score | 0.15 | Foundation controls that enable others are prioritized across IT, OT, and clinical environments |
| E Effort-to-Value | 0.15 | High-impact controls relative to implementation effort surface first in the remediation roadmap |
| B Blast Radius | 0.15 | Controls preventing manufacturing shutdowns or large-scale clinical data exposure receive a boost |
| R Regulatory Criticality | 0.20 | Highest weight — controls tied to FDA 21 CFR Part 11, HIPAA, and NIH/DoD requirements are prioritized first |
| C Coverage Breadth | 0.10 | Controls addressing multiple attack vectors across IT, OT, and clinical domains are prioritized |
| A Asset Exposure | 0.05 | Controls protecting IP, clinical trial data, and manufacturing systems weighted accordingly |
Regulatory Criticality and Threat Relevance share the highest weighting — FDA requirements and nation-state IP theft threats both demand that compliance-critical and threat-mitigating controls be addressed first.
Read the Full UCPA MethodologyStart free with the Coverage Aggregator or run a full CIS Controls or NIST CSF assessment tailored for pharmaceutical and clinical environments.